Screener
Sarepta Therapeutics, Inc. SRPT Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
FAQ
- What is Sarepta Therapeutics, Inc.'s total liabilities?
- Sarepta Therapeutics, Inc. (SRPT) reported total liabilities of $1.66B in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s total liabilities changed year-over-year?
- Sarepta Therapeutics, Inc.'s total liabilities decreased by 28.5% year-over-year, from $2.32B to $1.66B.
- What is the long-term trend for Sarepta Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Sarepta Therapeutics, Inc.'s total liabilities has grown at a -0.1% compound annual growth rate (CAGR), from $2.22B to $2.21B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Sarepta Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude